Mathias Schmidt

Chief Executive Officer & Executive Fellow ArmaGen & JCR Pharmaceuticals

The Lundquist Institute (TLI) is pleased to welcome Mathias Schmidt, PD, PhD, to its Board of Directors. A life sciences leader with over 25 years of experience in biopharma, Schmidt has dedicated his career to advancing therapies that improve the lives of patients, particularly in rare and pediatric diseases.

Mathias Schmidt currently serves as Chief Executive Officer of ArmaGen, Inc., and as Executive Fellow and Advisor to the Chairman of JCR Pharmaceuticals, Ltd. Over the course of his career, he has led companies through financing rounds, mergers, and international expansion, while keeping patients and outcomes at the center of his work.

At ArmaGen, Schmidt helped advance a blood-brain-barrier platform and guided the first phase II clinical trial of a brain-penetrant therapy for children with severe MPS I. He later expanded JCR’s global rare-disease portfolio and built lasting collaborations across the biopharma ecosystem. Earlier in his career, he held leadership roles at ASTA Medica, Altana, Nycomed, and Takeda California, and trained at MD Anderson Cancer Center in Houston.

Seminars

Tuesday 1st December 2026
Right Drug, Right Target, Right Delivery Route: Building Fit-for-Purpose CNS Delivery Strategies
1:00 pm

As the number of available CNS delivery technologies continues to expand, developers face a growing challenge: determining which approach is best suited to their specific therapeutic goal. While BBB shuttles, intrathecal administration, implantable devices, focused ultrasound, gene therapy vectors and emerging non-invasive approaches each offer unique advantages, their suitability can vary dramatically depending on the target, modality, disease biology and patient population. This interactive workshop will move beyond debates around which technology is ‘best’ to explore how developers can build fit for- purpose delivery strategies that maximize clinical, operational and commercial success.

This Workshop Will Gather Experts To:

  • Define how factors including target location, therapeutic modality, required biodistribution and dosing frequency should influence CNS delivery strategy selection
  • Compare where systemic delivery, direct CNS administration, device-enabled approaches and BBB modulation technologies offer the greatest advantages across different disease settings
  • Explore the trade-offs between efficacy, safety, patient burden, operational complexity and scalability when evaluating delivery options for chronic versus acute indications
  • Develop a practical framework for matching delivery technologies to specific program goals, therapeutic modalities and target product profiles
Wednesday 2nd December 2026
Keynote: Why is it so much Harder to Deliver Oligonucleotides to the Brain Compared to Other Organs?
8:50 am
  • Exploring that the rate-limiting step for oligonucleotides targeted for CNS indications is release of oligonucleotides from lysosome and brain tissue
  • Evaluating novel delivery technologies across LNPs, ultrasound, viral particles and routes of administration in delivering oligonucleotides to the brain without compromising on potency, distribution, affinity or efficacy
  • Reviewing the next step to optimizing structural design to ensure delivery to the cytoplasm and nucleus
Mathias Schmidt, President and Chief Executive Officer of ArmaGen and JCR Pharmaceuticals at the 8th CNS Drug Delivery Summit